Summary Nasopharyngeal carcinomas (NPC) are common in Hong Kong and southern China but rare in Western countries. Telomerase activation is common in human cancers but has not been reported previously in NPC. Telomerase activation in NPC was determined using the sensitive TRAP (telomerase rapid amplification protocol) assay in 45 nasopharyngeal biopsies (36 NPC, nine normal nasopharyngeal mucosae) in four xenografted NPC tumours established in nude mice and in five in vitro NPC cell lines. Telomerase activation is common in NPC and can be detected at high frequencies (85% in primary tumours and 100% in recurrent tumours). The frequency of telomerase activation was lowest in NPC biopsies without lymph node involvement (60%) compared with those with positive lymph node involvement (100%), and the difference is statistically significant (P < 0.05; Fisher exact test). All the xenografted NPC tumours and in vitro NPC cell lines were strongly positive for telomerase activity. Our results suggest that telomerase activation is common in NPC and it may be useful as a diagnostic marker in the detection of tumour cells in nasopharyngeal biopsies. The high frequency of telomerase activation in stage I NPC (80% positive) suggests that it is an early event in tumour progression.
Nasopharyngeal carcinoma (NPC) is a common cancer in Hong Kong and the southem China region. The incidence of NPC in Chinese living in Hong Kong, South China, Taiwan and Singapore is 25 times higher than Caucasians living in the European and American continents (Muir et al, 1987) . The molecular basis of the pathogenesis of NPC is poorly understood. In contrast to many other human cancers, mutations of the p53 and Rb genes are uncommon events in NPC (Spruck et al, 1992; Sun et al, 1993) . Homozygous deletion of chromosome 9p is common in NPC and involves the pi6 gene (Lo et al, 1995) . In addition, loss of heterozygosity involving chromosome 3p is a common event in NPC . We have recently mapped a common region of deletion at chromosome 3pl3-14.3 in NPC , involving the locus of a recently cloned tumour-suppressor gene (FHIT) . Aberrant transcripts of the FHIT gene were also detected in NPC cell lines .
The incidence of NPC starts to increase at around age 20-24 years, peaks at age 40-60 years and then gradually decreases . NPC responds well to radiation therapy, which is the major treatment modality at present . NPC diagnosed at its early stage is associated with better prognosis. A marker capable of detecting the presence of tumour cells in NPC biopsies would be particularly useful in the early diagnosis of NPC. Such a marker would also be useful in the detection of tumour cells in residual tumour after radiation treatment.
Telomerase is a ribonucleoprotein enzyme that maintains the telomeric length at chromosomal ends with simple repetitive sequences (Avilion et al, 1996) . It compensates for the end replication problem associated with cell division and allows cells to proliferate indefinitely (Kim et al, 1994) . Telomerase activation is common in malignant transformation (Chadeneau et al, 1995) . Prognostic value of telomerase activation has been implicated in some human cancers, such as neuroblastoma (Hiyama et al, 1995a) and gastric cancers (Hiyama et al, 1995b) . Telomerase activation in NPC has not been previously investigated, and its usefulness in clinical application is completely unknown. In this study, we have examined telomerase activity in biopsied NPC tissues obtained from primary and recurrent nasopharyngeal cancers and have evaluated its potential application as a malignant marker for the detection of tumour cells in NPC biopsies.
MATERIALS AND METHODS NPC biopsies, cell lines and xenografted NPC
Forty-five nasopharyngeal biopsies (36 tumours and nine nonneoplastic nasopharyngeal tissues) were obtained for this study. Informed consents for the use of clinical materials for telomerase study were obtained from patients. The NPC biopsies used in this study were examined by cryosectioning to confirm the absence or presence of tumour cells. The biopsies were then extracted and assayed for telomerase activity. All the NPC biopsies, except those from recurrent cancers, were collected from patients before chemotherapy or radiotherapy. Nine non-cancerous nasopharyngeal mucosae were obtained as controls and they were obtained either from patients undergoing radical head and neck surgery or from patients with suspected NPC lesions but later confirmed to be negative for NPC. All the non-neoplastic nasopharyngeal tissues were confirmed histologically to be free of tumour cells.
The establishment of the xenografted NPC tumours, 2117 and 666, and the in vitro cell lines, HK1, CNE1, CNE2 and 666, has been previously published (Gu et al, 1983; Huang et al, 1980, 
Clinical staging
The clinical staging of the nasopharyngeal carcinomas was according to the TNM staging system (reviewed by Wei and Sham, 1994 
TRAP assay
Telomerase activity was determined using the TRAP assay according to previously published procedures (Piatyszek et al, 1995) . All precautions for RNAase contamination were observed. Tumour tissues or cell pellets were homogenized by a motorized disposable pestle (VWR Scientific, Sugar Land, TX, USA) in cold CHAPS buffer (10 mm Tris-HCI pH 7.5, 1 mm magnesium chloride, 1 mM EGTA, 0.1 mm phenylmethylsulphonyl fluoride,
The homogenate was kept on ice for 30 min and spun at 12 000 g for 30 min at 4°C. The supernatant was carefully removed and the protein concentration was determined by Coomassie protein assay reagent (Pierce Chemical, Rockford, IL, USA). To dilute out the effect of telomerase inhibitors that may be present in the sample extract, telomerase activity from each specimen was assayed at two concentrations (1 x, 10 x dilutions). All the samples that were negative for telomerase were mixed with positive telomerase control and reassayed for telomerase activity to confirm the absence of telomerase inhibitor in the sample extract. Assay tubes were prepared by sequestering 0.1 gg of CX primer (5'-CCCTFACCCTTACCCTTACCCTAA- I1  I1  I1  I1  11  11  11  11  11  111  111  111  111  111  IV  IV  IV  IV  IV  IV  IV Ti NO Ti NO Ti NO Ti NO Ti NO  T1Nl  Ti NI  T2NO  T2NO  T2NO  T2NO  T2N1  T2N1  T2N1  T2N1  T2N2  Ti N2  Ti N2  T2N2  T3NO  T2N3  T3N2  T3N3  T3N1  T3N1  Ti 
Western analysis of cytokeratin in NPC biopsies RESULTS
Apart from histological confirmation of tumour cells in the NPC biopsies, we have also examined the presence of keratin in these biopsies to confirm the presence of epithelial cells (Tsao et al, 1995) . RNAase inactivation, which confirmned the specificity of the assay.
Activation of telomerase was common in established cell lines of NPC (Table 2 ). All established NPC cell lines examined were positive for telomerase activity. These included four xenografted NPC lines (2117, 666, METI, MET2) (Figure 1 ) established in nude mice and four in vitro NPC cell lines (CNEI, CNE2, HKI, 391, 666) (Figure 2 ).
DISCUSSION
This is the first report of telomerase activation in NPC. In line with observations in other human malignancies (Kim et al, 1994; Chadeneau et al, 1995) , telomerase activation is also a common event in NPC. Telomerase activity can be detected at high frequency (89%) in NPC biopsies and in all NPC cell lines examined. Non-neoplastic nasopharyngeal mucosae were negative for telomerase activity. This is in agreement with the observation that telomerase activation is closely associated with malignancies but not with hyperplasia or benign tumours in other human cancers (Chadeneau et al, 1995; Tahara et al, 1995; Hiyama et al, 1996; Sommerfeld et al, 1996) . The association of telomerase with cell immortalization has been demonstrated in several cell systems, including EBV-immortalized human lymphocytes (Counter et al, 1994) . It was shown that telomerase activation was not detected in the early phase of proliferation of B-lymphocytes after infection with EBV. Telomerase activity was detected only in the immortalized B-cell clones at the later stage of EBV immortalization. This unique property of telomerase distinguishes it from other proliferative markers, such as PCNA and Ki67, which are closely associated with proliferation. In this study, we only detected telomerase activation in NPC tissues but not in non-neoplastic nasopharyngeal biopsies. This is in line with the general observation that telomerase is detected in immortalized and cancer cells but not in mortal somatic cells. In NPC, telomerase activation was observed in all stages of diseases, suggesting that it is an early event in tumour progression. A higher frequency of telomerase activation was observed in advanced NPC compared with early diseases, however the difference is not statistically significant (P > 0.5). The sample size in this study may be small for the observation to be conclusive. There were four histologically confirmed NPC biopsies (all from early stages) with negative telomerase activity. The clinical significance of these telomerase-negative NPCs is not fully understood at this stage; the clinical history of these telomerase-negative NPC patients will be followed closely to examine any influence on survival or recurrence of the disease. Another observation is that telomerase activation appears to be more frequent in NPC biopsies with positive lymph node metastasis (100% positive rate) than those without lymph node involvement (60%) (P < 0.05, Fisher exact test), suggesting a positive association of telomerase activity with tumour progression. Other clinical features examined included tumour differentiation and serological EBV markers, but no obvious relationship with telomerase activation has been observed (Table 1) .
In view of the high frequency of telomerase activation in NPC, the detection of telomerase activity alone may have limited prognostic value for NPC patients. The prognostic value of the level of telomerase activation in NPC remains to be determined. However, the high frequency of telomerase activation in NPC biopsies and its close association with tumour cells suggests that it may be useful as a malignant marker for the detection of tumour cells in NPC biopsies. Hence, the telomerase activity may complement the existing methods used for the diagnosis of NPC, such as serological markers (e.g. IgA/EBV, IgA/EA) and the PCR method for EBV. In support of this, we were able to detect telomerase activity in two NPC biopsies (HKNPC 18 and 44) that were seronegative for EBV VCA. As EBV is present in both NPC cells and lymphocytes in biopsies, the use of the PCR method alone will not give conclusive evidence for the presence of tumour cells in NPC biopsies. The telomerase assay has the advantage over the PCR method in detecting not only EBV-positive cells but also immortalized tumour cells. The detection of high telomerase activity in nasopharyngeal biopsies may warrant further examinations, including repeated biopsies from the patients and careful monitoring of serological markers for NPC. Another potential application of the telomerase assay may be in the detection of submicroscopic tumour foci or premalignant but immortal lesions that may escape histopathological examination.
